Seprafilm cuts uterine adhesions
This article was originally published in Clinica
Executive Summary
Genzyme's Seprafilm significantly reduced gynaecological adhesions in a trial presented at the European Society for Gynaecological Endoscopy in Brussels last week (December 8th). Dr Michael Diamond, professor of obstetrics and gynaecology at Wayne State University in Detroit, said that fibroid patients treated with the film have 37% fewer lesions than untreated women. The adhesions in the treated group were also significantly less severe and smaller, he added.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.